Jun 19 2015
Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
The Vectibix treatment arm further showed statistical significance for all key secondary endpoints including OS in patients with wild-type RAS (absence of mutations in exons 2, 3 and 4 of KRAS and NRAS) mCRC.
In the Vectibix treatment arm, the observed adverse events were consistent with the known Vectibix safety profile.
Full results will be submitted to a future medical congress and for publication.
"Amgen has been at the forefront of researching personalized approaches to treating cancer, and the Vectibix clinical program continues to underscore the importance of identifying options for patients based on their cancer's genetic makeup," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "These positive overall survival results for Vectibix reinforce the importance of KRAS and RAS biomarkers in making treatment decisions in metastatic colorectal cancer."
Colorectal cancer is the third most common cancer worldwide, with approximately 1.2 million cases occuring globally each year. In the U.S., colorectal cancer is the second leading cause of cancer-related deaths, with an estimated 132,700 new cases diagnosed in 2015. In Europe, colorectal cancer is the second most common cancer, with approximately 470,000 new cases each year.
SOURCE Amgen
Air pollution linked to head and neck cancer risk